Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on ...
Bristol Myers Squibb BMY recently announced that it will discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) ...
Bristol Myers Squibb BMY announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the ...
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 ...
Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The news ...
Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results